Insider Trading Alert - ACHC, ARO And ICPT Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Aug. 27, 2014, 98 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $66.82 to $18,231,262.91.

Highlighted Stocks Traded by Insiders:

Acadia Healthcare (ACHC) - FREE Research Report

Grieco William, who is Director at Acadia Healthcare, sold 4,522 shares at $50.67 on Aug. 27, 2014. Following this transaction, the Director owned 29,762 shares meaning that the stake was reduced by 13.19% with the 4,522-share transaction.

The shares most recently traded at $51.17, up $0.50, or 0.98% since the insider transaction. Historical insider transactions for Acadia Healthcare go as follows:

  • 4-Week # shares sold: 10,889
  • 12-Week # shares sold: 10,889
  • 24-Week # shares sold: 94,242

The average volume for Acadia Healthcare has been 476,800 shares per day over the past 30 days. Acadia Healthcare has a market cap of $3.1 billion and is part of the health care sector and health services industry. Shares are up 9.82% year-to-date as of the close of trading on Wednesday.

Acadia Healthcare Company, Inc. develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, and substance abuse facilities in the United States. The company has a P/E ratio of 42.0. Currently, there are 7 analysts who rate Acadia Healthcare a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACHC - FREE

TheStreet Quant Ratings rates Acadia Healthcare as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Acadia Healthcare Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Aeropostale (ARO) - FREE Research Report

Gilman Kenneth B, who is Director at Aeropostale, bought 30,000 shares at $3.83 on Aug. 27, 2014. Following this transaction, the Director owned 61,532 shares meaning that the stake was boosted by 95.14% with the 30,000-share transaction.

The shares most recently traded at $4.12, up $0.29, or 7.05% since the insider transaction. Historical insider transactions for Aeropostale go as follows:

  • 4-Week # shares bought: 55,000
  • 4-Week # shares sold: 7,721
  • 12-Week # shares bought: 55,000
  • 12-Week # shares sold: 7,721
  • 24-Week # shares bought: 55,000
  • 24-Week # shares sold: 7,721

The average volume for Aeropostale has been 3.4 million shares per day over the past 30 days. Aeropostale has a market cap of $300.4 million and is part of the services sector and retail industry. Shares are down 54.24% year-to-date as of the close of trading on Wednesday.

Aeropostale, Inc., together with its subsidiaries, operates as a mall-based specialty retailer of casual apparel and accessories. Currently, there are no analysts who rate Aeropostale a buy, 2 analysts rate it a sell, and 18 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARO - FREE

TheStreet Quant Ratings rates Aeropostale as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, poor profit margins, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Aeropostale Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Intercept Pharmaceuticals (ICPT) - FREE Research Report

Williams Nicole, who is Director at Intercept Pharmaceuticals, sold 2,433 shares at $295.08 on Aug. 27, 2014. Following this transaction, the Director owned 1,465 shares meaning that the stake was reduced by 62.42% with the 2,433-share transaction.

The shares most recently traded at $298.09, up $3.01, or 1.01% since the insider transaction. Historical insider transactions for Intercept Pharmaceuticals go as follows:

  • 4-Week # shares sold: 774
  • 12-Week # shares sold: 774
  • 24-Week # shares sold: 3,659

The average volume for Intercept Pharmaceuticals has been 536,500 shares per day over the past 30 days. Intercept Pharmaceuticals has a market cap of $6.4 billion and is part of the health care sector and drugs industry. Shares are up 332.44% year-to-date as of the close of trading on Wednesday.

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. The company has a P/E ratio of 56.3. Currently, there are 5 analysts who rate Intercept Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ICPT - FREE

TheStreet Quant Ratings rates Intercept Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and feeble growth in the company's earnings per share. Get the full Intercept Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices